Pharmaceuticals and Healthcare

Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome

The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.

BeOne Medicines and partners renew Brukinsa access programme for CLL

BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.

Fulcrum and Slate Medicines sign merger agreement

Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors.

EMA validates Pfizer and Valneva’s Lyme disease vaccine

The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.

Remepy secures $36m funding for hybrid drug pipeline expansion

Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline.

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib

China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.

Aptar unveils framework for injectable drug delivery systems

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.

JCVI issues recommendation on adolescent MenB vaccination in UK

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.